CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenues:
Total revenues	$ 1,616,141	$ 633,519
Cost of revenues	242,562	232,031
Operating expenses:
Selling, general and administrative	3,500,904	2,373,413
Research and development	748,365	564,426
Depreciation and amortization	97,412	75,067
Total operating expenses	4,346,681	3,012,906
LOSS FROM OPERATIONS	(2,973,102)	(2,611,418)
Other (expense) income:
Interest expense, net	(5,438)	(29,091)
Loss on extinguishment of debt	(1,774,662)	0
Other expense, net	(53,860)	(22,232)
Loss before provision for income taxes	(4,807,062)	(2,662,741)
Provision for income taxes	0	0
NET LOSS	(4,807,062)	(2,662,741)
Less: Net (income) loss attributable to noncontrolling interest	(2,494)	30
NET LOSS attributable to Applied DNA Sciences, Inc.	(4,809,556)	(2,662,711)
Deemed dividend related to warrant modifications		(2,842)
NET LOSS applicable to common stockholders	$ (4,809,556)	$ (2,665,553)
Net loss per share applicable to common stockholders - basic and diluted	$ (0.88)	$ (1.12)
Weighted average shares outstanding - basic and diluted	5,457,967	2,380,564
Product
Revenues:
Total revenues	$ 550,097	$ 237,870
Service
Revenues:
Total revenues	$ 1,066,044	$ 395,649